Effect of Once-Weekly Teriparatide for Bisphosphonate-Resisitance Glucocorticoid-Induced Osteoporosis (TeriGo)
Not Applicable
- Conditions
- Glucocorticoid-Induced Osteoporosis
- Registration Number
- JPRN-UMIN000021987
- Lead Sponsor
- Teikyo University School of Medicine (Hajime Kono) Toho University School of Medicine (Toshihiro Nanki)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients whose BMD of 3 or more of lumbar spines cannot be analysed because of fracture or artificial materials. 2) Contraindication for bisphosphonate or teriparatide. 3) Patients who have received teriparatide or denosumab. 4) Patients with active infection or malignancy. 5) Age less than 20 years old. 6) Patients who is currently pregnant, breastfeeding or willing to get pregnant. 7) Patients who do not give consent to the study. 8) Patients who are judged to be inappropriate by the physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome is the change of bone mineral density in hip and lumbar spine (L1-4).
- Secondary Outcome Measures
Name Time Method